Kalaris Therapeutics's top three insider shareholders as of August 04, 2026 are Morana Jovan-Embiricos (Director, 26.50Mn shares), Llc Elevatebio, (Director, 16.67Mn shares), Ansbert Gadicke (Director, 16.67Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Sciences, Inc. Gilead | - | 16,635,286 | 0 | 28 Jun, 2023 |
| Ansbert Gadicke | - | 0 | 16,674,766 | 01 Aug, 2022 |
| Srinivas Akkaraju | - | 0 | 11,444,503 | 18 Mar, 2025 |
| Samir Chandrakant Patel | - | 252,000 | 100,800 | 18 Mar, 2025 |
| Vikas Sinha | - | 0 | 16,674,766 | 01 Aug, 2022 |
| David Hallal | - | 0 | 16,674,766 | 01 Aug, 2022 |
| Morana Jovan-Embiricos | - | 0 | 26,502,857 | 01 Aug, 2022 |
| Jeffrey S Bornstein | - | 110,197 | 0 | 07 Jun, 2024 |
| Shawn Tomasello | - | 70,000 | 0 | 07 Jun, 2024 |
| Edward Miller | General Counsel | 0 | 346,348 | 11 Dec, 2024 |
| Matthew Feinsod | Chief Medical Officer | 4,030 | 0 | 18 Mar, 2025 |
| Beek Jeroen B Van | Chief Commercial Officer | 333,726 | 0 | 18 Nov, 2022 |
| Napoleone Ferrara | - | 504,000 | 0 | 18 Mar, 2025 |
| Juan Vera | - | 2,409,928 | 0 | 07 Jun, 2024 |
| Llc Elevatebio, | - | 16,674,766 | 0 | 01 Aug, 2022 |
| Agustin Melian | Chief Medical Officer | 453,529 | 0 | 05 Oct, 2021 |
| Malcolm Brenner | - | 100,197 | 0 | 07 Jun, 2024 |
| Ercem Atillasoy | - | 131,372 | 0 | 26 Oct, 2022 |
| Cintia Piccina | Chief Commercial Officer | 147,000 | 0 | 05 Jul, 2023 |
| Derek N. Adams | - | 70,000 | 0 | 07 Jun, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 20 Mar, 2026 | Brett R Hagen | Common Stock | D | 1,915 | $6.72 | 0 | D | S |
| 19 Mar, 2026 | Brett R Hagen | Stock Option (Right to Buy) | A | 60,800 | $0.00 | 60,800 | D | A |
| 19 Mar, 2026 | Matthew Feinsod | Stock Option (Right to Buy) | A | 135,000 | $0.00 | 135,000 | D | A |
| 19 Mar, 2026 | Andrew Oxtoby | Stock Option (Right to Buy) | A | 222,000 | $0.00 | 222,000 | D | A |
| 19 Mar, 2026 | Andrew Oxtoby | Stock Option (Right to Buy) | A | 222,000 | $0.00 | 222,000 | D | A |
| 19 Mar, 2026 | Andrew Oxtoby | Stock Option (Right to Buy) | A | 222,000 | $0.00 | 222,000 | D | A |
| 19 Mar, 2026 | Matthew Gall | Stock Option (Right to Buy) | A | 95,000 | $0.00 | 95,000 | D | A |
| 18 Dec, 2025 | Srinivas Akkaraju | Common Stock | A | 479,847 | $10.42 | 1,979,847 | I | P |
| 22 Dec, 2025 | Srinivas Akkaraju | Common Stock | A | 1,500,000 | $10.00 | 1,500,000 | I | A |
| 03 Nov, 2025 | Matthew Gall | Stock Option (Right to Buy) | A | 235,000 | $0.00 | 235,000 | D | A |
| 10 Apr, 2025 | Leone D Patterson | Stock Option (Right to Buy) | A | 18,000 | $0.00 | 18,000 | D | A |
| 10 Apr, 2025 | Morana Jovan-Embiricos | Stock Option (Right to Buy) | A | 18,000 | $0.00 | 18,000 | D | A |
| 10 Apr, 2025 | Matthew Feinsod | Stock Option (Right to Buy) | A | 70,551 | $0.00 | 70,551 | D | A |
| 10 Apr, 2025 | Samir Chandrakant Patel | Stock Option (Right to Buy) | A | 18,000 | $0.00 | 18,000 | D | A |
| 10 Apr, 2025 | Napoleone Ferrara | Stock Option (Right to Buy) | A | 18,000 | $0.00 | 18,000 | D | A |
| 10 Apr, 2025 | David Hallal | Stock Option (Right to Buy) | A | 18,000 | $0.00 | 18,000 | D | A |
| 10 Apr, 2025 | Michael Dybbs | Stock Option (Right to Buy) | A | 18,000 | $0.00 | 18,000 | D | A |
| 10 Apr, 2025 | Andrew Oxtoby | Stock Option (Right to Buy) | A | 287,000 | $0.00 | 287,000 | D | A |
| 10 Apr, 2025 | Samir Chandrakant Patel | Stock Option (Right to Buy) | A | 18,000 | $0.00 | 18,000 | D | A |
| 10 Apr, 2025 | Andrew Oxtoby | Stock Option (Right to Buy) | A | 287,000 | $0.00 | 287,000 | D | A |